REPORTS: Martin Shkreli, the former pharma executive everyone loves to hate, may face new charges
AP Photo/Richard Drew
Martin Shkreli talking to Maria Bartiromo on Fox Business Network.
Shkreli already faces charges he defrauded investors, but his lawyers said Tuesday that a trial should be delayed, as there may be new charges filed.
CNBC reports those additional charges against Shkreli and lawyer Evan Greebel should be announced within the month.
To recap, Shkreli has been charged by the federal government with seven counts:
- 2 counts of securities fraud
- 2 counts of conspiracy to commit securities fraud
- 3 counts of conspiracy to commit wire fraud.
Shkreli, the notorious former pharma CEO, made headlines last September after he raised the price of Daraprim, a drug used to treat a parasitic infection called toxoplasmosis, by 5,000%. These charges, however, are not directly related to the price hike, but to events that happened earlier in his career, while he was managing hedge funds.
Shkreli's next court appearance is scheduled for June 6, CNBC reports.
Next Story
I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
One of the world's only 5-star airlines seems to be considering asking business-class passengers to bring their own cutlery
From terrace to table: 8 Edible plants you can grow in your home
India fourth largest military spender globally in 2023: SIPRI report
New study forecasts high chance of record-breaking heat and humidity in India in the coming months
Gold plunges ₹1,450 to ₹72,200, silver prices dive by ₹2,300
Strong domestic demand supporting India's growth: Morgan Stanley
